

Edgar Filing: SANOFI-AVENTIS - Form 6-K

SANOFI-AVENTIS
Form 6-K
November 30, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2004

Commission File Number: 001-31368

SANOFI-AVENTIS
(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F [X]

Form 40-F []

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes []

No [X]

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____

On November 29, 2004, Sanofi-Aventis (formerly known as Sanofi-Synthelabo) issued the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

EXHIBIT LIST

EXHIBIT NO. -----	DESCRIPTION -----
Exhibit 99.1	Press Release, dated November 29, 2004, announcing that ELOXATIN(TM) (oxaliplatin for injection) based therapy combined with bevacizumab (AVATIN(TM)) significantly improves survival in patients with advanced colorectal cancer.

Edgar Filing: SANOFI-AVENTIS - Form 6-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 30, 2004

SANOFI-AVENTIS

By: /s/ Jean-Claude Leroy

Name: Jean-Claude Leroy
Title: Senior Vice President &
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO. -----	DESCRIPTION -----
Exhibit 99.1	Press Release, dated November 29, 2004, announcing that ELOXATIN(TM) (oxaliplatin for injection) based therapy combined with bevacizumab (AVATIN(TM)) significantly improves survival in patients with advanced colorectal cancer.